As distribution of Moderna, Inc.’s COVID-19 vaccine begins, post-authorization pharmacovigilance systems maintained by the US Centers for Disease Control and Prevention will be particularly interested in any potential anaphylaxis reactions.
No such reactions were seen in Moderna’s trial, but none had been observed in the trial of the Pfizer...







